WO2008063727A3 - Combination therapy for treatment of viral infections - Google Patents

Combination therapy for treatment of viral infections Download PDF

Info

Publication number
WO2008063727A3
WO2008063727A3 PCT/US2007/076435 US2007076435W WO2008063727A3 WO 2008063727 A3 WO2008063727 A3 WO 2008063727A3 US 2007076435 W US2007076435 W US 2007076435W WO 2008063727 A3 WO2008063727 A3 WO 2008063727A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
antiviral compound
combination therapy
viral infections
time period
Prior art date
Application number
PCT/US2007/076435
Other languages
French (fr)
Other versions
WO2008063727A2 (en
Inventor
Roger Jeffs
S Karl Gotzkowsky
Raymond Allen Dwek
Nicole Zitzmann
Original Assignee
United Therapeutics Corp
Roger Jeffs
S Karl Gotzkowsky
Raymond Allen Dwek
Nicole Zitzmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp, Roger Jeffs, S Karl Gotzkowsky, Raymond Allen Dwek, Nicole Zitzmann filed Critical United Therapeutics Corp
Priority to EP07870157A priority Critical patent/EP2054076A2/en
Priority to JP2009525739A priority patent/JP2010510171A/en
Priority to CA002666814A priority patent/CA2666814A1/en
Publication of WO2008063727A2 publication Critical patent/WO2008063727A2/en
Publication of WO2008063727A3 publication Critical patent/WO2008063727A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

One can treat a viral infection by first administering at least one first antiviral compound for a first time period and then, after the end of the first time period, concurrently or subsequently administering the at least one first antiviral compound and at least one second antiviral compound for a second period. In some cases, after the end of the second period, the same at least one second antiviral compound that was administered during the second time period may be administered for a third time period without concurrent or subsequent administration of the at least one first antiviral compound.
PCT/US2007/076435 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections WO2008063727A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07870157A EP2054076A2 (en) 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections
JP2009525739A JP2010510171A (en) 2006-08-21 2007-08-21 Combination therapy for the treatment of viral infections
CA002666814A CA2666814A1 (en) 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83887206P 2006-08-21 2006-08-21
US60/838,872 2006-08-21
US87449806P 2006-12-13 2006-12-13
US60/874,498 2006-12-13
US89430707P 2007-03-12 2007-03-12
US60/894,307 2007-03-12

Publications (2)

Publication Number Publication Date
WO2008063727A2 WO2008063727A2 (en) 2008-05-29
WO2008063727A3 true WO2008063727A3 (en) 2009-01-08

Family

ID=39426663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/076435 WO2008063727A2 (en) 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections

Country Status (6)

Country Link
US (2) US20080131398A1 (en)
EP (1) EP2054076A2 (en)
JP (1) JP2010510171A (en)
KR (1) KR20090057035A (en)
CA (1) CA2666814A1 (en)
WO (1) WO2008063727A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049126A2 (en) * 2006-08-02 2009-04-22 United Therapeutics Corporation Liposome treatment of viral infections
CN102046151A (en) * 2008-03-26 2011-05-04 牛津大学 Endoplasmic reticulum targeting liposomes
WO2010096764A1 (en) * 2009-02-23 2010-08-26 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
ES2562635T3 (en) * 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares and methods of treatment of infections caused by arenavirus
CA2757026A1 (en) 2009-03-27 2010-09-30 The Chancellor, Masters And Scholars Of The University Of Oxford Cholesterol level lowering liposomes
CN102639133B (en) * 2009-06-12 2015-03-11 联合治疗公司 Iminosugars and methods of treating bunyaviral and togaviral diseases
DK2473482T3 (en) * 2009-09-04 2014-05-12 United Therapeutics Corp Methods of treating orthomyxoviral infections
CN105748476A (en) * 2009-09-04 2016-07-13 联合治疗公司 Iminosugars And Methods Of Treating Filoviral Diseases
JP5575246B2 (en) * 2009-09-04 2014-08-20 ユナイテッド セラピューティクス コーポレイション How to treat poxvirus infection
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
US8569255B2 (en) 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
ES2572328B1 (en) 2011-10-21 2017-08-24 Abbvie Inc. COMBINATION OF AT LEAST TWO ANTIVIRAL AGENTS OF DIRECT ACTION AND RIBAVIRINA BUT NOT INTERFERED, FOR USE IN THE TREATMENT OF HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112015001690A2 (en) 2012-07-24 2017-11-07 Pharmacyclics Inc mutations associated with resistance to bruton tyrosine kinase inhibitors (btk)
BR112015010059A2 (en) 2012-11-02 2017-07-11 Pharmacyclics Inc adjuvant therapy with the tec family kinase inhibitor
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
BR112018077032A2 (en) * 2016-06-23 2019-04-02 Nutrivert Llc method for enhancing growth or feed conversion in an animal, use of pgn, mdp or an mdp analog in the preparation of a medicament and pgn, mdp or an mdp analog
FR3057773B1 (en) 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 NOVEL ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS-RELATED INFECTIONS
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
KR20210089659A (en) 2018-10-05 2021-07-16 제노세라퓨틱스, 인코포레이티드 Xenograft products and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089780A2 (en) * 2001-05-03 2002-11-14 Virogen Ltd Antiviral compounds
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2006037227A1 (en) * 2004-10-06 2006-04-13 Migenix Inc. Combination anti-viral compositions comprising castanospermine and methods of use

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241704B1 (en) * 1901-11-22 2001-06-05 Sims Deltec, Inc. Drug pump systems and methods
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
NO154918C (en) * 1977-08-27 1987-01-14 Bayer Ag ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE.
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
DE2834122A1 (en) * 1978-08-03 1980-02-14 Bayer Ag METHOD FOR PRODUCING 6-AMINO-6-DESOXY-L-SORBOSE
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
DE2853573A1 (en) * 1978-12-12 1980-07-03 Bayer Ag PREPARATION OF N-SUBSTITUTED DERIVATIVES OF L-DESOXYNOJIRIMYCIN
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4350155A (en) * 1980-04-02 1982-09-21 Medtronic, Inc. Body implantable medical infusion system
US4311137A (en) * 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
DE3038901A1 (en) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4531937A (en) * 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4725852A (en) * 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
DE3543999A1 (en) * 1985-12-13 1987-06-19 Bayer Ag HIGH PURITY ACARBOSE
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
DE3611841A1 (en) * 1986-04-09 1987-10-15 Bayer Ag METHOD FOR PRODUCING 1-DESOXYNOJIRIMYCIN AND ITS N-DERIVATIVES
US4861892A (en) * 1988-02-12 1989-08-29 G. D. Searle & Co. Method for synthesis of deoxymannojirimycin
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4855173A (en) * 1988-08-11 1989-08-08 Dore Peter B Repair process for a fibre reinforced structure
US4910310A (en) * 1988-10-03 1990-03-20 G. D. Searle & Co. Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives
US4894388A (en) * 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
US5011929A (en) * 1989-05-15 1991-04-30 Monsanto Company Synthesis of mannojirimycin derivatives
US5017704A (en) * 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5100797A (en) * 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US4996329A (en) * 1989-10-20 1991-02-26 Monsanto Company Derivatives of 1,4-dideoxy-1,4-imino-D-mannitol and a process for their preparation
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5151519A (en) * 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
JP3162123B2 (en) * 1990-09-20 2001-04-25 モンサント カンパニー Method for producing N-substituted-1-deoxynojirimycin
US5200523A (en) * 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5401645A (en) * 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545143A (en) * 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5286877A (en) * 1993-02-01 1994-02-15 G. D. Searle & Co. Synthesis of 1,4-dideoxy-1,4-imino-L-arabinitol
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
JP3628021B2 (en) * 1994-01-13 2005-03-09 ジー．ディー．サール アンド カンパニー Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of hepatitis B virus infection
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5443450A (en) * 1994-04-29 1995-08-22 Medtronic, Inc. Medication delivery device and method of construction
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
DE19509634C1 (en) * 1995-03-17 1996-03-28 Fresenius Ag Implantable infusion pump with constant delivery rate
US5643207A (en) * 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ATE284202T1 (en) * 1996-02-02 2004-12-15 Alza Corp IMPLANTABLE DELAYED RELEASE SYSTEM
CZ126799A3 (en) * 1996-10-16 1999-07-14 Icn Pharmaceuticals Purine l-nucleosides and their analogs as well as pharmaceutical composition containing thereof
ZA979327B (en) * 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
GB2324223A (en) * 1997-04-11 1998-10-14 Northern Telecom Ltd Network management
US6171276B1 (en) * 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
PE20000066A1 (en) * 1997-12-22 2000-02-09 Schering Corp SOLID DOSAGE FORMS OF ORALLY ADMINISTRABLE RIBAVIRIN AND MANUFACTURING PROCESS
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
JP4690545B2 (en) * 1998-03-31 2011-06-01 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1109580A4 (en) * 1998-09-04 2004-05-26 Viropharma Inc Methods for treating or preventing viral infections and associated diseases
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6308099B1 (en) * 1998-11-13 2001-10-23 Intermedics Inc. Implantable device and programmer system which permits multiple programmers
EP1165080A2 (en) * 1999-02-12 2002-01-02 G.D. SEARLE & CO. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6198966B1 (en) * 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
WO2001060366A1 (en) * 2000-02-14 2001-08-23 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
DK1268425T3 (en) * 2000-03-29 2008-05-05 Vertex Pharma Carbamate caspase inhibitors and their use
EP1283827A2 (en) * 2000-05-23 2003-02-19 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
DE10031274A1 (en) * 2000-06-27 2002-01-10 Bosch Gmbh Robert Wiper arm for motor vehicles
AU2002348971A1 (en) * 2001-10-12 2003-04-28 Stefana M. Petrescu Ph-sensitive liposomes for targeted drug delivery
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
KR20070053229A (en) * 2004-08-13 2007-05-23 미게닉스 인코포레이티드 Compositions and methods for treating or preventing hepadnaviridae infection
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
JP2008530124A (en) * 2005-02-09 2008-08-07 ミジェニックス インコーポレイテッド Compositions and methods for treating or preventing flavivirus infections
EP2049126A2 (en) * 2006-08-02 2009-04-22 United Therapeutics Corporation Liposome treatment of viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089780A2 (en) * 2001-05-03 2002-11-14 Virogen Ltd Antiviral compounds
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2006037227A1 (en) * 2004-10-06 2006-04-13 Migenix Inc. Combination anti-viral compositions comprising castanospermine and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTIVIRAL RESEARCH, vol. 55, no. 3, September 2002 (2002-09-01), pages 425 - 435, ISSN: 0166-3542 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2002 (2002-09-01), OUZOUNOV SERGUEY ET AL: "The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: Implications for hepatitis C virus (HCV) therapy", XP002482101, Database accession no. PREV200200536946 *
WHITBY KEVIN ET AL: "ACTION OF CELGOSIVIR (6 O-BUTANOYL CASTANOSPERMINE) AGAINST THE PESTIVIRUS BVDV: IMPLICATIONS FOR THE TREATMENT OF HEPATITIS C", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, BLACKWELL SCIENTIFIC PUBL., LONDON, GB, vol. 15, no. 3, 1 May 2004 (2004-05-01), pages 141 - 151, XP009072691, ISSN: 0956-3202 *

Also Published As

Publication number Publication date
US20080131398A1 (en) 2008-06-05
WO2008063727A2 (en) 2008-05-29
CA2666814A1 (en) 2008-05-29
EP2054076A2 (en) 2009-05-06
US20130195798A1 (en) 2013-08-01
KR20090057035A (en) 2009-06-03
JP2010510171A (en) 2010-04-02

Similar Documents

Publication Publication Date Title
WO2008063727A3 (en) Combination therapy for treatment of viral infections
WO2010045656A3 (en) Novel sglt2 inhibitor dosage forms
MY141025A (en) Dose forms
WO2006006172A3 (en) Use of anti-amyloid agents for treating and typing pathogen infections
WO2009052411A3 (en) Methods for treatment of thiol-containing compound deficient conditions
WO2005089738A3 (en) Use and administration of bacterial efflux pump inhibitors
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
MX2014002171A (en) Combination treatments for hepatitis c.
WO2007111866A3 (en) Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
BRPI0812738A2 (en) COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR THE TREATMENT OF A VIRAL INFECTION IN A HUMAN
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
BRPI0920605A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and method for the treatment or prophylaxis of HIV infection or for the treatment, prophylaxis, or delay in the onset or progression of AIDS in a patient in need thereof.
WO2007030944A3 (en) Methods of cardioprotection using dichloroacetate in combination with an inotrope
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2010019717A3 (en) Combination therapy of hiv fusion/entry inhibitors targeting gp41
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780034965.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007870157

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870157

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2666814

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009525739

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 530/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020097005854

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU